September 24 (Reuters) – U.S. drug maker Moderna Inc (MRNA.O) will deliver 20 million doses of its COVID-19 vaccine to Peru, with deliveries starting in the first quarter of 2022.
Moderna said on Friday that she would work with regulators across the country to get the necessary approvals before the distribution of her vaccine, which is currently not approved for use in Peru.
The country has so far vaccinated around 37.6% of its population, according to the latest Reuters tally.
The Andean nation has also signed agreements with the American company Pfizer Inc (PFE.N), the Anglo-Swedish company AstraZeneca (AZN.L) and the Chinese company Sinopharm. Peru bought 20 million doses of Russian Sputnik V in July.
There have been 2,169,427 infections and 199,108 coronavirus-related deaths reported in Peru since the start of the pandemic, according to a Reuters tally.
In June, the Biden administration announced that it was shipping 2 million doses of the Pfizer COVID-19 vaccine to Peru.
Report by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli
Our standards: Thomson Reuters Trust Principles.